Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 294 | 49 | 241 |
| Samples | 158 | 35 | 121 |
| Peptides | 121 | 28 | 101 |
Function
PDGFB · Platelet derived growth factor subunit B
This gene encodes a member of the protein family comprised of both platelet-derived growth factors (PDGF) and vascular endothelial growth factors (VEGF). The encoded preproprotein is proteolytically processed to generate platelet-derived growth factor subunit B, which can homodimerize, or alternatively, heterodimerize with the related platelet-derived growth factor subunit A. These proteins bind and activate PDGF receptor tyrosine kinases, which play a role in a wide range of developmental processes. Mutations in this gene are associated with meningioma. Reciprocal translocations between chromosomes 22 and 17, at sites where this gene and that for collagen type 1, alpha 1 are located, are associated with dermatofibrosarcoma protuberans, a rare skin tumor. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Oct 2015].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 115 amino-acid changes on canonical ENST00000331163 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PDGFB · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PDGFB – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Chondrosarcoma | 2/14 14% | 0/75 0% |
| Endometrial Carcinoma | 3/42 7% | 9/612 1% |
| Colorectal Carcinoma | 8/143 6% | 27/3239 1% |
| Melanoma | 2/210 1% | 16/1899 1% |
| Gastric Carcinoma | 0/74 0% | 15/1809 1% |
| Hodgkins Lymphoma | 1/16 6% | 0/122 0% |
| Other Sarcomas | 1/69 1% | 3/699 0% |
| Thyroid Gland Carcinoma | 2/45 4% | 6/1592 0% |
| Non-Small Cell Lung Carcinoma | 4/304 1% | 4/1390 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 4/810 0% |
| Burkitts Lymphoma | 1/32 3% | 0/196 0% |
| Other Solid Cancers | 0/94 0% | 7/1515 0% |
| Non-Cancerous | 0/104 0% | 4/830 0% |
| Ewings Sarcoma | 1/63 2% | 0/262 0% |
| Head and Neck Carcinoma | 0/85 0% | 5/1574 0% |
| Pancreatic Carcinoma | 0/89 0% | 4/1611 0% |
| Breast Carcinoma | 2/144 1% | 5/3264 0% |
| Bladder Carcinoma | 0/58 0% | 2/956 0% |
| Hepatocellular Carcinoma | 0/46 0% | 4/2210 0% |
| Ovarian Carcinoma | 1/109 1% | 1/998 0% |
| Neuroendocrine Tumour | 1/154 1% | 0/577 0% |
| Esophageal Carcinoma | 0/23 0% | 1/769 0% |
| Other Blood Cancers | 1/61 2% | 2/2725 0% |
| Biliary Tract Carcinoma | 1/54 2% | 0/950 0% |
| Prostate Carcinoma | 0/13 0% | 2/2105 0% |
| Esophageal Squamous Cell Carcinoma | 1/51 2% | 1/2550 0% |
| Kidney Carcinoma | 1/85 1% | 0/1862 0% |
| B-Lymphoblastic Leukemia | 0/55 0% | 1/2640 0% |
Mutation Distribution
Where PDGFB is mutated · all tissues, split by cell line vs tissue
How many mutations in PDGFB were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 294 mutations in PDGFB
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|